DPP-4 inhibitors do not cause weight gain compared with the impact of a rapid decrease in blood glucagon, and because they act dependently on blood glucagon concentrations in the body, they have a low risk of hypoglycemia and are used as an adjuvant to dietary and exercise therapy [15,16]. Here, GCG is linked to Hypoglycemia.